Bio Vitos Pharma AB

Equities

BIOVIT

SE0009320278

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 11:22:17 2024-05-21 EDT			5-day change	1st Jan Change
0.16 ^SEK	+5.96%		-1.84%	-32.77%

02-14	Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-14	Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023

February 14, 2024 at 02:30 am

Bio Vitos Pharma AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 3 million compared to SEK 4.74 million a year ago. Revenue was SEK 3 million compared to SEK 4.74 million a year ago.

Net loss was SEK 12.87 million compared to SEK 14.9 million a year ago.

Latest news about Bio Vitos Pharma AB

Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-14	CI
Bio Vitos Pharma Teams Up with KFUM Kalmar to Explore Benefits of Iron Succinate for Female Athletes	02-12	MT
KFUM Kalmar and Bio Vitos Pharma Sign Collaboration Agreement to Conduct Research Study on Succifer	02-12	CI
The European Patent Office EPO Grants Patent to Bio Vitos Pharma AB	12-20	CI
Hemcheck Sweden AB will Change its Ticker to BIOVIT from HEMC	12-06	CI
Hemcheck Sweden AB will Change its Name to Bio Vitos Pharma AB	12-06	CI
Hemcheck Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Hemcheck Sweden AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Hemcheck Sweden AB Receives A First Order from Its Distributor Astemed	23-05-15	CI
Hemcheck Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Hemcheck Sweden Receives New Follow Up Order from the Foundation for Innovative New Diagnostics	23-04-26	CI
Hemcheck Sweden AB Receives First Order from the University Hospital Charité in Berlin	23-04-05	CI
Hemcheck Sweden AB Receives First Follow Up Order from Its Finnish Distributor	23-03-13	CI
Hemcheck Sweden AB Receives an Additional Follow-Up Order from Its Uk Distributor	23-03-02	CI
Hemcheck Receives Follow Up Order from Research Program in the United States	23-02-28	CI
Hemcheck Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-14	CI
Hemcheck Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
YRRO Ltd agreed to acquire Hemcheck Sweden AB (OM:HEMC) in a reverse merger transaction for SEK 85.7 million.	23-02-07	CI
Hemcheck Sweden AB Receives Follow-Up Order from Eurobio Scientific	23-02-03	CI
Hemcheck Sweden AB Receives Follow-Up Order from CLS	23-02-01	CI
Hemcheck Receives First Order from Landspitali	23-01-24	CI
Hemcheck Receives a Follow Up Order from Its Spanish Distributor	23-01-23	CI
Hemcheck Receives Another Follow Up Order from Its Irish Distributor	23-01-16	CI
Hemcheck Sweden AB Extends Agreement Regarding Previously Communicated Project with Region Skåne	23-01-03	CI

Chart Bio Vitos Pharma AB

Duration

Period

More charts

Company Profile

Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIO VITOS PHARMA AB	-32.77%	4.15M
BIOMÉRIEUX	-6.26%	12.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.17B
DIASORIN S.P.A.	+7.10%	5.78B
LANTHEUS HOLDINGS, INC.	+30.16%	5.74B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.24B
10X GENOMICS, INC.	-57.20%	2.97B
ANDON HEALTH CO., LTD.	+12.56%	2.73B
VITROLIFE AB	-4.67%	2.38B
MYRIAD GENETICS, INC.	+27.38%	2.26B

Diagnostic & Testing Substances